Renal cell carcinoma

Cancer Biomarkers

Volumn 9, Issue 1-6, 2011, Pages 461-473

  Cairns, Paul ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

chromophobe; clear cell; diagnosis; end stage renal disease (ESRD); epigenetics; genetics; hypermethylation; multifocal; natural history; papillary; precursor lesion; prognosis; Renal cell carcinoma (RCC); small renal masses (SRM); therapy

Indexed keywords

MICRORNA; MOLECULAR MARKER;

AGING; ARTICLE; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CANCER STAGING; CELL TYPE; CLEAR CELL CARCINOMA; CLINICAL FEATURE; COPY NUMBER VARIATION; EARLY DIAGNOSIS; EPIGENETICS; GENE EXPRESSION; GENE SEQUENCE; GENETIC IDENTIFICATION; GENETIC PREDISPOSITION; GENETICS; HISTORY; HUMAN; INCIDENTAL FINDING; KIDNEY CARCINOMA; KIDNEY TUMOR; MEDICAL LITERATURE; METHYLATION; MORTALITY; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; TUMOR SUPPRESSOR GENE;

CARCINOMA, RENAL CELL; EARLY DETECTION OF CANCER; EPIGENESIS, GENETIC; HUMANS; INCIDENCE; KIDNEY NEOPLASMS; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 82955180319     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-2011-0176     Document Type: Article

References (122)

1. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu and M. J. Thun, Cancer statistics, 2009, CA Cancer J Clin 59 (2009), 225-249.
2. P. Russo, Contemporary understanding and management of renal cortical tumors, Urol Clin North Am 35 (2008), xiii- xvii.
3. G. J. Decastro and J. M. McKiernan, Epidemiology, clinical staging, and presentation of renal cell carcinoma, Urol Clin North Am 35 (2008), 581-592; vi.
4. R. Dhote, M. Pellicer-Coeuret, N. Thiounn, B. Debre and G. Vidal-Trecan, Risk factors for adult renal cell carcinoma: a systematic review and implications for prevention, BJU Int 86 (2000), 20-27.
5. R. P. Gibbons, J. E. Monte, R. J. Correa, Jr. and J. T. Mason, Manifestations of renal cell carcinoma, Urology 8 (1976), 201-206.
6. H. T. Cohen and F. J. McGovern, Renal-cell carcinoma, N Engl J Med 353 (2005), 2477-2490.
7. P. A. Jones, N. J. Vogelzang and J. A. O. Gomez, Report of the Kidney/BladderCancer Progress ReviewGroup, NCI (2002).
8. T. E. Hutson and R. A. Figlin, Novel therapeutics formetastatic renal cell carcinoma, Cancer 115 (2009), 2361-2367.
9. G. Kovacs, M. Akhtar, B. J. Beckwith et al. , The Heidelberg classification of renal cell tumours, J Pathol 183 (1997), 131-133.
10. American Joint Committee on Cancer, AJCC Cancer Staging Handbook - 7th Ed. , Springer, 2010.
11. L. M. Hock, J. Lynch and K. C. Balaji, Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: an analysis of surveillance, epidemiology and end results program data, J Urol 167 (2002), 57-60.
12. B. Delahunt, P. B. Bethwaite and J. N. Nacey, Outcome prediction for renal cell carcinoma: evaluation of prognostic factors for tumours divided according to histological subtype, Pathology 39 (2007), 459-465.
13. B. Delahunt, Advances and controversies in grading and staging of renal cell carcinoma, Mod Pathol 22(Suppl 2) (2009), S24-36.
14. C. P. Pavlovich and L. S. Schmidt, Searching for the hereditary causes of renal-cell carcinoma, Nat Rev Cancer 4 (2004), 381-393.
15. F. Latif, K. Tory, J. Gnarra et al. , Identification of the von Hippel-Lindau disease tumor suppressor gene, Science 260 (1993), 1317-1320.
16. C. P. Pavlovich, L. S. Schmidt and J. L. Phillips, The genetic basis of renal cell carcinoma, Urol Clin North Am 30 (2003), 437-454, vii.
17. J. R. Gnarra, K. Tory, Y. Weng et al. , Mutations of the VHL tumour suppressor gene in renal carcinoma, Nature Genet 7 (1994), 85-90.
18. G. L. Dalgliesh, K. Furge, C. Greenman et al. , Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes, Nature (2010).
19. E. Dulaimi, I. Ibanez De Caceres, R. G. Uzzo et al. , Promoter Hypermethylation Profile of Kidney Cancer, Clinical Cancer Research (2004).
20. J. D. Gordan, P. Lal, V. R. Dondeti et al. , HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma, Cancer Cell 14 (2008), 435-446.
21. W. G. Kaelin, Jr. , The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma, Clin Cancer Res 13 (2007), 680s-684s.
22. W. M. Linehan and B. Zbar, Focus on kidney cancer, Cancer Cell 6 (2004), 223-228.
23. R. K. Thomas, A. C. Baker, R. M. Debiasi et al. , Highthroughput oncogene mutation profiling in human cancer, Nat Genet 39 (2007), 347-351.
24. R. Beroukhim, J. P. Brunet, A. Di Napoli et al. , Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney, Cancer Res 69 (2009), 4674-4681.
25. H. Moch, G. Sauter, T. C. Gasser et al. , EGF-r gene copy number changes in renal cell carcinoma detected by fluorescence in situ hybridization, J Pathol 184 (1998), 424-429.
26. H. Moch, G. Sauter, N. Buchholz et al. , Epidermal growth factor receptor expression is associated with rapid tumor cell proliferation in renal cell carcinoma, Hum Pathol 28 (1997), 1255-1259.
27. P. Schraml, J. Kononen, L. Bubendorf et al. , Tissue microarrays for gene amplification surveys in many different tumor types, Clin Cancer Res 5 (1999), 1966-1975.
28. U. Weidner, S. Peter, T. Strohmeyer, R. Hussnatter, R. Ackermann and H. Sies, Inverse relationship of epidermal growth factor receptor and HER2/neu gene expression in human renal cell carcinoma, Cancer Res 50 (1990), 4504-4509.
29. G. Kovacs, S. Szucs, W. De Riese and H. Baumgartel, Specific chromosome aberration in human renal cell carcinoma, Int J Cancer 40 (1987), 171-178.
30. C. A. Thrash-Bingham, R. E. Greenberg, S. Howard et al. , Comprehensive allelotyping of human renal cell carcinomas using microsatellite DNA probes, Proc Natl Acad Sci USA 92 (1995), 2854-2858.
31. M. Wilhelm, J. A. Veltman, A. B. Olshen et al. , Array-based comparative genomic hybridization for the differential diagnosis of renal cell cancer, Cancer Res 62 (2002), 957-960.
32. P. Cairns, T. J. Polascik, Y. Eby et al. , Frequency of homozygous deletion at p16/CDKN2 in primary human tumours, Nature Genet 11 (1995), 210-212.
33. H. Haibach, T. W. Burns, H. E. Carlson, K. D. Burman and L. J. Deftos, Multiple hamartoma syndrome (Cowden's disease) associated with renal cell carcinoma and primary neuroendocrine carcinoma of the skin (Merkel cell carcinoma) Am J Clin Pathol 97 (1992), 705-712.
34. P. Cairns, E. Evron, K. Okami et al. , Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers, Oncogene 16 (1998), 3215-3218.
35. M. A. Zysman,W. B. Chapman and B. Bapat, Considerations when analyzing the methylation status of PTEN tumor suppressor gene, Am J Pathol 160 (2002), 795-800.
36. C. Stolle, G. Glenn, B. Zbar et al. , Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene, Hum Mutat 12 (1998), 417-423.
37. G. Kovacs, A. Emanuel, H. P. Neumann and H. F. Kung, Cytogenetics of renal cell carcinomas associated with von Hippel- Lindau disease, Genes Chromosomes Cancer 3 (1991), 256-262.
38. M. Takahashi, D. R. Rhodes, K. A. Furge et al. , Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification, Proc Natl Acad Sci U S A 98 (2001), 9754-9759.
39. J. R. Vasselli, J. H. Shih, S. R. Iyengar et al. , Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor, Proc Natl Acad Sci U S A 100 (2003), 6958-6963.
40. J. Jones, H. Otu, D. Spentzos et al. , Gene signatures of progression and metastasis in renal cell cancer, Clin Cancer Res 11 (2005), 5730-5739.
41. J. P. Higgins, R. Shinghal, H. Gill et al. , Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray, Am J Pathol 162 (2003), 925-932.
42. M. Takahashi, X. J. Yang, J. Sugimura et al. , Molecular subclassification of kidney tumors and the discovery of new diagnostic markers, Oncogene 22 (2003), 6810-6818.
43. A. N. Young, M. B. Amin, C. S. Moreno et al. , Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers, Am J Pathol 158 (2001), 1639-1651.
44. S. Rohan, J. J. Tu, J. Kao et al. , Gene expression profiling separates chromophobe renal cell carcinoma from oncocytoma and identifies vesicular transport and cell junction proteins as differentially expressed genes, Clinical Cancer Research 12 (2006), 6937-6945.
45. X. J. Yang, M. H. Tan, H. L. Kim et al. , A molecular classification of papillary renal cell carcinoma, Cancer Res 65 (2005), 5628-5637.
46. M. Abdulrahman, E. N. Maina, M. R. Morris et al. , Identification of novel VHL targets that are associated with the development of renal cell carcinoma, Oncogene 26 (2007), 1661-1672.
47. E. N. Maina, M. R. Morris, M. Zatyka et al. , Identification of novel VHL target genes and relationship to hypoxic response pathways, Oncogene 24 (2005), 4549-4558.
48. K. A. Furge, M. H. Tan, K. Dykema et al. , Identification of deregulated oncogenic pathways in renal cell carcinoma: an integrated oncogenomic approach based on gene expression profiling, Oncogene 26 (2007), 1346-1350.
49. B. Bussolati, S. Bruno, C. Grange, U. Ferrando and G. Camussi, Identification of a tumor-initiating stem cell population in human renal carcinomas, FASEB J 22 (2008), 3696-3705.
50. I. Ibanez de Caceres, E. Dulaimi, A. M. Hoffman, T. Al- Saleem, R. G. Uzzo and P. Cairns, Identification of novel arget genes by an epigenetic reactivation screen of renal cancer, Cancer Res 66 (2006), 5021-5028.
51. J. G. Herman, F. Latif, Y. Weng et al. , Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma, Proc Natl Acad Sci USA 91 (1994), 9700-9704.
52. N. F. da Silva, D. Gentle, L. B. Hesson, D. G. Morton, F. Latif and E. R. Maher, Analysis of the Birt-Hogg-Dube (BHD) tumour suppressor gene in sporadic renal cell carcinoma and colorectal cancer, J Med Genet 40 (2003), 820-824.
53. S. Gad, S. H. Lefevre, S. K. Khoo et al. , Mutations in BHD and TP53 genes, but not in HNF1beta gene, in a large series of sporadic chromophobe renal cell carcinoma, Br J Cancer 96 (2007), 336-340.
54. M. Esteller, A. Sparks, M. Toyota et al. , Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer, Cancer Res 60 (2000), 4366-4371.
55. E. Dahl, F. Wiesmann, M. Woenckhaus et al. , Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma, Oncogene 26 (2007), 5680-5691.
56. S. Urakami, H. Shiina, H. Enokida et al. , Combination analysis of hypermethylated Wnt-antagonist family genes as a novel epigenetic biomarker panel for bladder cancer detection, Clin Cancer Res 12 (2006), 2109-2116.
57. A. Hoffman and P. Cairns, Kidney and Bladder Cancer Epigenetics, Epigenomics in press, 2010.
58. M. Jung, H. J. Mollenkopf, C. Grimm et al. , MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy, J Cell Mol Med 13 (2009), 3918-3928.
59. C. Nakada, K. Matsuura, Y. Tsukamoto et al. , Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c, J Pathol 216 (2008), 418-427.
60. D. Juan, G. Alexe, T. Antes et al. , Identification of aMicroRNA Panel for Clear-cell Kidney Cancer, Urology (2009).
61. L. Schmidt, F. M. Duh, F. Chen et al. , Germline and somatic mutations in the tyrosine kinase domain of the MET protooncogene in papillary renal carcinomas, NatGenet 16 (1997), 68-73.
62. Z. Zhuang, W. S. Park, S. Pack et al. , Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas, Nat Genet 20 (1998), 66-69.
63. J. Fischer, G. Palmedo, R. von Knobloch et al. , Duplication and overexpression of the mutant allele of the MET protooncogene in multiple hereditary papillary renal cell tumours, Oncogene 17 (1998), 733-739.
64. L. Schmidt, K. Junker, N. Nakaigawa et al. , Novel mutations of the MET proto-oncogene in papillary renal carcinomas, Oncogene 18 (1999), 2343-2350.
65. B. Delahunt and J. N. Eble, Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors, Mod Pathol 10 (1997), 537-544.
66. A. Szponar, D. Zubakov, J. Pawlak, A. Jauch and G. Kovacs, Three genetic developmental stages of papillary renal cell tumors: duplication of chromosome 1q marks fatal progression, Int J Cancer 124 (2009), 2071-2076.
67. B. Delahunt, J. N. Eble, M. R. McCredie, P. B. Bethwaite, J. H. Stewart and A. M. Bilous, Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases, Hum Pathol 32 (2001), 590-595.
68. I. A. Lubensky, L. Schmidt, Z. Zhuang et al. , Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype, Am J Pathol 155 (1999), 517-526.
69. I. P. Tomlinson, N. A. Alam, A. J. Rowan et al. , Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer, Nat Genet 30 (2002), 406-410.
70. M. Kiuru, R. Lehtonen, J. Arola et al. , Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families, Cancer Res 62 (2002), 4554-4557.
71. G. Kovacs, L. Fuzesi, A. Emanual and H. F. Kung, Cytogenetics of papillary renal cell tumors, Genes Chromosomes Cancer 3 (1991), 249-255.
72. G. Kovacs, Molecular cytogenetics of renal cell tumors, Adv Cancer Res 62 (1993), 89-124.
73. P. Cairns, K. Tokino, Y. Eby and D. Sidransky, Localization of tumor suppressor loci on chromosome 9 in primary human renal cell carcinomas, Cancer Res 55 (1995), 224-227.
74. D. Schullerus, J. Herbers, J. Chudek, H. Kanamaru and G. Kovacs, Loss of heterozygosity at chromosomes 8p, 9p, and 14q is associated with stage and grade of non-papillary renal cell carcinomas, J Pathol 183 (1997), 151-155.
75. M. R. Speicher, B. Schoell, S. du Manoir et al. , Specific loss of chromosomes 1, 2, 6, 10, 13, 17, and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridizati n, Am J Pathol 145 (1994), 356-364.
76. P. Bugert and G. Kovacs, Molecular differential diagnosis of renal cell carcinomas by microsatellite analysis, Am J Pathol 149 (1996), 2081-2088.
77. C. Kenck, M. Wilhelm, P. Bugert, G. Staehler and G. Kovacs, Mutation of the VHL gene is associated exclusively with the development of non-papillary renal cell carcinomas, J Pathol 179 (1996), 157-161.
78. H. Contractor, M. Zariwala, P. Bugert, J. Zeisler and G. Kovacs, Mutation of the p53 tumour suppressor gene occurs preferentially in the chromophobe type of renal cell tumour, J Pathol 181 (1997), 136-139.
79. K. Yamazaki, M. Sakamoto, T. Ohta, Y. Kanai, M. Ohki and S. Hirohashi, Overexpression of KIT in chromophobe renalcell carci oma, Oncogene 22 (2003), 847-852.
80. A. Haitel, M. Susani, N. Wick, P. R. Mazal and F. Wrba, c-kit overexpression in chromophobe renal cell carcinoma is not associated with c-kit mutation of exons 9 and 11, Am J Surg Pathol 29 (2005), 842.
81. J. R. Toro, M. H. Wei, G. M. Glenn et al. , BHD mutations, clinical and molecular genetic investigations of Birt-Hogg- Dube syndrome: a new series of 50 families and a review of published reports, J Med Genet 45 (2008), 321-331.
82. M. L. Nickerson, M. B. Warren, J. R. Toro et al. , Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome, Cancer Cell 2 (2002), 157-164.
83. S. K. Khoo, K. Kahnoski, J. Sugimura et al. , Inactivation of BHD in sporadic renal tumors, Cancer Res 63 (2003), 4583-4587.
84. A. Nagy, D. Zoubakov, Z. Stupar and G. Kovacs, Lack of mutation of the folliculin gene in sporadic chromophobe renal cell carcinoma and renal oncocytoma, Int J Cancer 109 (2004), 472-475.
85. T. J. Polascik, P. Cairns, J. I. Epstein et al. , Distal nephron renal tumors: microsatellite allelotype, Cancer Res 56 (1996), 1892-1895.
86. G. Steiner, P. Cairns, T. J. Polascik et al. , High-density mapping of chromosomal arm 1q in renal collecting duct carcinoma: region of minimal deletion at 1q32. 1-32. 2, Cancer Res 56 (1996), 5044-5046.
87. M. Schoenberg, P. Cairns, J. D. Brooks et al. , Frequent loss of chromosome arms 8p and 13q in collecting duct carcinoma (CDC) of the kidney, Genes Chromosomes Cancer 12 (1995), 76-80.
88. J. R. Srigley and B. Delahunt, Uncommon and recently described renal carcinomas, Mod Pathol 22(Suppl 2) (2009), S2-S23.
89. J. Presti, J. C. H. Moch, A. B. Gelb, D. Huynh and F. M. Waldman, Initiating genetic events in small renal neoplasms detected by comparative genomic hybridization, J Urol 160 (1998), 1557-1561.
90. H. Van Poppel, S. Nilsson, F. Algaba et al. , Precancerous lesions in the kidney, Scand J Urol Nephrol Suppl (2000), 136-165.
91. I. A. Lubensky, J. R. Gnarra, P. Bertheau,M. M. Walther,W. M. Linehan and Z. Zhuang, Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients, Am J Pathol 149 (1996), 2089-2094.
92. K. Junker, K. Thrum, A. Schlichter, G. Muller, W. Hindermann and J. Schubert, Clonal origin of multifocal renal cell carcinoma as determined by microsatellite analysis, J Urol 168 (2002), 2632-2636.
93. H. Miyake, H. Nakamura, I. Hara et al. , Multifocal renal cell carcinoma: evidence for a common clonal origin, Clin Cancer Res 4 (1998), 2491-2494.
94. L. Cheng, G. T. MacLennan, S. Zhang et al. , Evidence for polyclonal origin ofmultifocal clear cell renal cell carcinoma, Clin Cancer Res 14 (2008), 8087-8093.
95. T. D. Jones, J. N. Eble, M. Wang et al. , Molecular genetic evidence for the independent origin of multifocal papillary tumors in patients with papillary renal cell carcinomas, Clin Cancer Res 11 (2005), 7226-7233.
96. G. Kovacs, Re: clonal origin of multifocal renal cell carcinoma as determined by microsatellite analysis, J Urol 170 (2003), 1325-1326; author reply 1326.
97. S. J. Jang and L. Mao, Methylation patterns in human androgen receptor gene and clonality analysis, Cancer Res 60 (2000), 864-866.
98. K. Gohji, I. Hara, A. Gotoh et al. , Multifocal renal cell carcinoma in Japanese patients with tumors with maximal diameters of 50 mm. or less, J Urol 159 (1998), 1144-1147.
99. S. C. Campbell, A. C. Novick, A. Belldegrun et al. , Guideline for management of the clinical T1 renal mass, J Urol 182 (2009), 1271-1279.
100. V. E. Reuter and J. C. Presti, Jr. , Contemporary approach to the classification of renal epithelial tumors, Semin Oncol 27 (2000), 124-137.
101. F. Wiklund, S. Tretli, T. K. Choueiri, S. Signoretti, K. Fall, H. O. Adami, Risk of bilateral renal cell cancer, J Clin Oncol 27 (2009), 3737-3741.
102. W. M. Linehan, Genetic basis of bilateral renal cancer: implications for evaluation and management, J Clin Oncol 27 (2009), 3731-3733.
103. A. Schwarz, S. Vatandaslar, S. Merkel and H. Haller, Renal cell carcinoma in transplant recipients with acquired cystic kidney disease, Clin J Am Soc Nephrol 2 (2007), 750-756.
104. G. M. Fick-Brosnahan, Polycystic and acquired cystic kidney disease. In: Primer on Kidney Diseases, A. Greenberg, ed. , San Francisco: Academic Press, 2001. pp. 303-308.
105. J. D. Scandling, Acquired cystic kidney disease and renal cell cancer after transplantation: time to rethink screening, Clin J Am Soc Nephrol 2 (2007), 621-622.
106. W. H. Chow, G. Gridley, J. F. Fraumeni, Jr. and B. Jarvholm, Obesity, hypertension, and the risk of kidney cancer in men, N Engl J Med 343 (2000), 1305-1311.
107. A. S. Parker, J. R. Cerhan, C. A. Janney, C. F. Lynch and K. P. Cantor, Smoking cessation and renal cell carcinoma, Ann Epidemiol 13 (2003), 245-251.
108. S. Karami, P. Brennan, M. Navratilova et al. , Vitamin d pathway genes, diet, and risk of renal cell carcinoma, Int J Endocrinol 2010 (2010), 879362.
109. R. C. Bast, Jr. , M. Brewer, C. Zou et al. , Prevention and early detection of ovarian cancer: mission impossible?, Recent Results Cancer Res 174 (2007), 91-100.
110. P. Cairns and D. Sidransky, Molecular methods for the diagnosis of cancer, Biochim Biophys Acta 1423 (1999), C11-C18.
111. P. Cairns, Gene methylation and early detection of genitourinary cancer: the road ahead, Nat Rev Cancer 7 (2007), 531-543.
112. C. Battagli, R. G. Uzzo, E. Dulaimi et al. , Promoter Hypermethylation of Tumor Suppressor Genes in Urine from Kidney Cancer Patients, Cancer Res 63 (2003), 8695-8699.
113. M. O. Hoque, S. Begum, O. Topaloglu et al. , Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer, Cancer Res 64 (2004), 5511-5517.
114. S. N. Chawla, P. L. Crispen, A. L. Hanlon, R. E. Greenberg, D. Y. Chen and R. G. Uzzo, The natural history of observed enhancing renal masses: meta-analysis and review of the world literature, J Urol 175 (2006), 425-431.
115. B. G. Duffey, P. L. Choyke, G. Glenn et al. , The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease, J Urol 172 (2004), 63-65.
116. J. A. Kontak and S. C. Campbell, Prognostic factors in renal cell carcinoma, Urol Clin North Am 30 (2003), 467-480.
117. J. S. Lam, T. Klatte, H. L. Kim et al. , Prognostic factors and selection for clinical studies of patients with kidney cancer, Crit Rev Oncol Hematol 65 (2008), 235-262.
118. L. Campbell, M. Gumbleton and D. F. Griffiths, Caveolin-1 overexpression predicts poor disease-free survival of patients with clinically confined renal cell carcinoma, Br J Cancer 89 (2003), 1909-1913.
119. E. R. Fearon andB. Vogelstein, Ageneticmodel for colorectal tumorigenesis, Cell 61 (1990), 759-767.
120. C. Béroud, J. -C. Fournet, C. Jeanpierre et al. , Correlations of allelic imbalance of chromosome 14 with adverse prognostic parameters in 148 renal cell carcinomas, Genes Chromosomes Cancer 17 (1996), 215-224.
121. H. Moch, J. C. Presti, Jr. , G. Sauter et al. , Genetic aberrations detected by comparative genomic hybridization are associated with clinical outcome in renal cell carcinoma, Cancer Res 56 (1996), 27-30.
122. P. Schraml, D. Muller, R. Bednar et al. , Allelic loss at the D9S171 locus on chromosome 9p13 is associated with progression of papillary renal cell carcinoma, J Pathol 190 (2000), 457-461.